Pulmonary Arterial Hypertension Epidemiology Study

Pulmonary Arterial Hypertension (PAH) Epidemiology Study Objective:

To determine the prevalence and incidence of Pulmonary Arterial Hypertension (PAH) among individuals in a defined population. This objective outlines the primary aim of the study, which is to establish the frequency of Pulmonary Arterial Hypertension (PAH) within a specific age group and geographic area, while also seeking to understand potential factors contributing to its development. Moreover, the report is having geographic coverage including North America, Europe and rest of the world however customisation can be made in the geographic coverage.

Pulmonary Arterial Hypertension (PAH) Study USP:

• This epidemiological study on Pulmonary Arterial Hypertension (PAH)stands out due to its comprehensive approach in establishing precise prevalence rates, identifying novel risk factors, and exploring geographical variations in a diverse population.


• By integrating advanced imaging techniques with robust statistical analyses, the study aims to provide actionable insights to identify treatment opportunities, target population, and an overview on public health initiatives aimed at mitigating the impact of Pulmonary Arterial Hypertension (PAH) related health problems.


• Through meticulous data collection and rigorous methodology, the study not only contributes to the scientific understanding of Pulmonary Arterial Hypertension (PAH) but also serves as a foundation for future research events and healthcare policymaking in addressing this increasing Pulmonary Arterial Hypertension (PAH) cases.

Pulmonary Arterial Hypertension (PAH) related Study Overview:

The study Defines Pulmonary Arterial Hypertension (PAH) as an advanced form of disease. The significance of studying Pulmonary Arterial Hypertension (PAH) epidemiology is due to its increasing prevalence in different age populations.

Pulmonary Arterial Hypertension (PAH) Study Design:

Population: The target population and the sampling method (e.g., random sampling from healthcare registries or population databases)

Data Collection: Detail methods for identifying Pulmonary Arterial Hypertension (PAH) cases (e.g., clinical examination, imaging studies) and demographic data (age, sex, ethnicity).

Pulmonary Arterial Hypertension (PAH) Epidemiological Parameters:

Prevalence: Prevalence rates considered per 1,000 or 10,000 population.

Incidence: Determine annual incidence rates per 1,000 person-years.

Risk Factors: Analyse associations between Pulmonary Arterial Hypertension (PAH) and potential risk factors (e.g., age, smoking, genetics).

Geographical Variations: Compare prevalence or incidence rates across different regions or countries.

Pulmonary Arterial Hypertension (PAH) study summary:

Pulmonary Arterial Hypertension (PAH) study summarizes the prevalence, incidence, possible risk factors, and geographic variations of the Pulmonary Arterial Hypertension (PAH) worldwide.

Pulmonary Arterial Hypertension (PAH) Disease overview:

Pulmonary Arterial hypertension (PAH) is a rare progressive disorder characterised by high blood pressure in the arteries of the lungs, which are called pulmonary arteries, caused by narrowing, tightening or blockage of these vessels making it harder for the heart to pump blood through them.

PAH is segmented into 7 classes in 6th World Symposium on Pulmonary Hypertension (WSPH) of 2019, based on the pathological mechanisms, causes, clinical signs and symptoms, hemodynamic features, and therapies into idiopathic PAH (IPAH), heritable PAH (HPAH); drug- and toxin-induced PAH; PAH associated with other conditions (such as connective tissue diseases, portal hypertension, and congenital heart disease); PAH in long-term responders to calcium channel blockers (CCBs); PAH with overt features of venous/capillaries involvement; and persistent PH of the newborn syndrome, mostly the more cases are found to be idiopathic PAH.

According to one of the study reported in the lancet respiratory medicine, in 2021, estimated prevalence cases of PAH were 192000 globally with 119 000 cases observed in females and 73100 cases in males. In 2021, 22 000 deaths were reported to be due to PAH globally, with an age-standardised mortality rate of 0·27 deaths 100 000 population.

Treatment options available in the market for this disease include Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Soluble Guanylate Cyclase Stimulators, Prostacyclin Analogues. Key market players manufacturing therapeutics for this disease are Pfizer, Sandoz, Actelion, United Therapeutics, Eli Lilly, Boehringer Ingelheim, GSK, Teva Pharmaceutical Industries, Novartis, Janssen Pharmaceuticals, Orphan Technologies, BristolMyers Squibb, Merck, AstraZeneca.

Pulmonary Arterial Hypertension (PAH) Demographic and Environmental Risk Factors:

Age and Sex:  According to the lancet study report, highest prevalence is observed in individuals aged 75 to 79 years, and the highest prevalence was seen in females with 62% and 38% in males, The age-standardised prevalence was 2·28 cases per 100 000 population, this disease is seen to affect more women or females or old population over age of 75.

Ethnicity:  white patients represent approximately 72.8% of PAH cases in U.S., black patients account about 12.2% of cases and have higher likelihood of developing PAH associated with connective tissue diseases like systemic sclerosis. Asian pacific islanders comprise 3.35 of cases.

Risk Factors causing Pulmonary Arterial Hypertension (PAH):

Family history, with two or more members of your family affected with PAH or anyone known to have a gene associated with PAH, are more likely to develop this disease. Obesity and obstructive sleep apnea are also seen to contribute in this disease development, Gender also plays role in development of PAH as; Idiopathic PAH and heritable PAH are more common in women compared to men. Females in childbearing age are seen to be more susceptible. People Living at a high altitude for years are more predisposed to PH. Other diseases, like congenital heart disease, lung disease, liver disease and connective tissue disorders like scleroderma and lupus, can become the reason of the development of pulmonary hypertension. drugs, like methamphetamines are found to cause pulmonary hypertension.

Pulmonary Arterial Hypertension (PAH) Market Scope:

Drivers: Increasing Prevalence of Pulmonary Arterial Hypertension

The Global Pulmonary Arterial Hypertension Market Industry is significantly driven by the rising prevalence of pulmonary arterial hypertension (PAH). According to the World Health Organization, it is estimated that approximately 15 to 50 cases of PAH exist per million people globally, with an observed increase in incidence over the past decade. As awareness and diagnostic capabilities improve, more individuals are being identified with PAH. For instance, recent studies highlighted a 25% rise in diagnosed cases in European countries due to enhanced screening practices and better understanding of the condition.

Organizations such as the European Society of Cardiology are actively promoting guidelines and campaigns to improve the diagnosis of PAH, thereby contributing to market growth in the Global Pulmonary Arterial Hypertension Market Industry. This increase in patient numbers is expected to drive demand for effective treatment options, pushing the market towards significant growth.

Restraints: Challenges may include regulatory hurdles like getting the approval for the therapeutics developed for the treatment is major challenge, which must show compliance to the regulatory standards set by the regulatory bodies failing of which will not allow the manufacturer to market the product and this process is mostly time consuming and competition from emerging therapies, with more and more companies doing research and development to find the best possible treatment options for the disease and the effective treatment options already available in the market are the competitors for the new manufacturers.